JP7382716B2 - 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）の予防または治療用医薬の調製におけるトリアセチル－３－ヒドロキシフェニルアデノシンの使用 - Google Patents

非アルコール性脂肪性肝疾患（ｎａｆｌｄ）の予防または治療用医薬の調製におけるトリアセチル－３－ヒドロキシフェニルアデノシンの使用 Download PDF

Info

Publication number
JP7382716B2
JP7382716B2 JP2018533743A JP2018533743A JP7382716B2 JP 7382716 B2 JP7382716 B2 JP 7382716B2 JP 2018533743 A JP2018533743 A JP 2018533743A JP 2018533743 A JP2018533743 A JP 2018533743A JP 7382716 B2 JP7382716 B2 JP 7382716B2
Authority
JP
Japan
Prior art keywords
nafld
alcoholic fatty
fatty liver
liver disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018533743A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019500379A5 (enExample
JP2019500379A (ja
Inventor
海波 朱
会杰 史
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Gushen Life Health Technology Co Ltd
Institute of Materia Medica of CAMS and PUMC
Original Assignee
Beijing Gushen Life Health Technology Co Ltd
Institute of Materia Medica of CAMS and PUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Gushen Life Health Technology Co Ltd, Institute of Materia Medica of CAMS and PUMC filed Critical Beijing Gushen Life Health Technology Co Ltd
Publication of JP2019500379A publication Critical patent/JP2019500379A/ja
Publication of JP2019500379A5 publication Critical patent/JP2019500379A5/ja
Application granted granted Critical
Publication of JP7382716B2 publication Critical patent/JP7382716B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2018533743A 2015-12-31 2016-12-28 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）の予防または治療用医薬の調製におけるトリアセチル－３－ヒドロキシフェニルアデノシンの使用 Active JP7382716B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201511034199 2015-12-31
CN201511034199.0 2015-12-31
PCT/CN2016/112623 WO2017114413A1 (zh) 2015-12-31 2016-12-28 三乙酰基-3-羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用

Publications (3)

Publication Number Publication Date
JP2019500379A JP2019500379A (ja) 2019-01-10
JP2019500379A5 JP2019500379A5 (enExample) 2020-02-13
JP7382716B2 true JP7382716B2 (ja) 2023-11-17

Family

ID=59224622

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018533743A Active JP7382716B2 (ja) 2015-12-31 2016-12-28 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）の予防または治療用医薬の調製におけるトリアセチル－３－ヒドロキシフェニルアデノシンの使用

Country Status (11)

Country Link
US (1) US11058703B2 (enExample)
EP (1) EP3398604A4 (enExample)
JP (1) JP7382716B2 (enExample)
KR (1) KR102676056B1 (enExample)
CN (2) CN106943420A (enExample)
AU (1) AU2016383376B2 (enExample)
CA (1) CA3010097C (enExample)
HK (1) HK1255689A1 (enExample)
RU (1) RU2759916C2 (enExample)
WO (1) WO2017114413A1 (enExample)
ZA (1) ZA201805080B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107334775A (zh) * 2016-03-14 2017-11-10 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备治疗动脉粥样硬化药物中的应用
KR20210016407A (ko) * 2018-06-05 2021-02-15 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 대사 장애 및 비알코올성 지방 간 질환의 치료를 위한 활성제 및 그 사용 방법
CN111821313A (zh) * 2019-04-17 2020-10-27 江苏天士力帝益药业有限公司 三乙酰基-3-羟基苯基腺苷在制备抑制心脏纤维化的药物中的应用
CN114869901B (zh) * 2022-05-06 2023-10-27 安徽医科大学 马鞭草苷在治疗酒精性肝损伤药物中的应用
CN117599076A (zh) * 2023-11-15 2024-02-27 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备运动模拟药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005132812A (ja) 2003-10-08 2005-05-26 Kobayashi Pharmaceut Co Ltd シイタケ菌糸体抽出物の分画物およびその用途
JP2007210926A (ja) 2006-02-08 2007-08-23 Tokyo Univ Of Pharmacy & Life Science ピラジンカルボン酸化合物からなる薬剤、及び食餌
JP2011196874A (ja) 2010-03-19 2011-10-06 Kanazawa Univ 肝保護作用を有するタンパク質、肝障害予防・保護用化合物のスクリーニング方法
JP2012519714A (ja) 2008-10-06 2012-08-30 中国医学科学院葯物研究所 トライアシル−３−ヒドロキシフェニルアデノシン及びその血中脂肪の調節用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100427534C (zh) * 2004-03-19 2008-10-22 四川大学 聚合物型含磷阻燃剂及其制备方法和用途
CN102125580A (zh) * 2011-01-17 2011-07-20 泰山医学院 三乙酰基-3-羟基苯基腺苷thpa在制药中的应用
ME02312B (me) * 2011-04-22 2016-06-20 Pfizer DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZE
AU2013204500A1 (en) 2012-09-21 2014-04-10 Barbara Jane Badenoch-Jones Novel AMPK agonist compositions and methods of use
CN103191145A (zh) 2013-03-27 2013-07-10 南京理工大学 腺苷及其衍生物在防治药物性肝损伤中的应用
CN104211747B (zh) * 2013-05-29 2018-09-25 中国医学科学院药物研究所 5’-磷酸-n6-（3-羟基苯基）腺苷的制备及医药用途
US9827222B2 (en) 2013-07-01 2017-11-28 Emory University Treating or preventing nephrogenic diabetes insipidus
CN104546887B (zh) * 2013-10-09 2018-10-30 中国医学科学院药物研究所 虫草素衍生物治疗炎症疾病的用途
CN105663152A (zh) 2014-11-19 2016-06-15 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备改善胰岛素抵抗及相关疾病中的应用
CN107334775A (zh) * 2016-03-14 2017-11-10 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备治疗动脉粥样硬化药物中的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005132812A (ja) 2003-10-08 2005-05-26 Kobayashi Pharmaceut Co Ltd シイタケ菌糸体抽出物の分画物およびその用途
JP2007210926A (ja) 2006-02-08 2007-08-23 Tokyo Univ Of Pharmacy & Life Science ピラジンカルボン酸化合物からなる薬剤、及び食餌
JP2012519714A (ja) 2008-10-06 2012-08-30 中国医学科学院葯物研究所 トライアシル−３−ヒドロキシフェニルアデノシン及びその血中脂肪の調節用途
JP2011196874A (ja) 2010-03-19 2011-10-06 Kanazawa Univ 肝保護作用を有するタンパク質、肝障害予防・保護用化合物のスクリーニング方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Ｌｉｐｉｄｓ ｉｎ Ｈｅａｌｔｈ ａｎｄ Ｄｉｓｅａｓｅ， ２０１１， １０， ｐ．６７（ｈｔｔｐ：／／ｗｗｗ．ｌｉｐｉｄｗｏｒｌｄ．ｃｏｍ／ｃｏｎｔｅｎｔ／１０／１／６７）
ＰＬｏＳ Ｏｎｅ， ２０１２， ７（３）， ｅ３２１１５
日本消化器病学会雑誌、２０１４年、１１１巻１号、４～１３頁
肝臓、１９８１年、２２巻１号、１２３頁

Also Published As

Publication number Publication date
US20190022120A1 (en) 2019-01-24
AU2016383376B2 (en) 2022-07-28
CA3010097C (en) 2023-08-22
KR20180100152A (ko) 2018-09-07
RU2018126158A (ru) 2020-01-31
AU2016383376A1 (en) 2018-07-12
EP3398604A1 (en) 2018-11-07
CN106943420A (zh) 2017-07-14
US11058703B2 (en) 2021-07-13
JP2019500379A (ja) 2019-01-10
KR102676056B1 (ko) 2024-06-19
RU2018126158A3 (enExample) 2020-03-11
CA3010097A1 (en) 2017-07-06
ZA201805080B (en) 2019-10-30
EP3398604A4 (en) 2019-06-19
WO2017114413A1 (zh) 2017-07-06
CN118178446A (zh) 2024-06-14
RU2759916C2 (ru) 2021-11-18
HK1255689A1 (en) 2019-08-23

Similar Documents

Publication Publication Date Title
JP7382716B2 (ja) 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）の予防または治療用医薬の調製におけるトリアセチル－３－ヒドロキシフェニルアデノシンの使用
US20160175253A1 (en) Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof
CN108619490A (zh) 一种长效化突变的人源成纤维生长因子的新用途
HK1244213A1 (zh) 预防或治疗脂肪肝的药物组合物
CN106176773A (zh) 盐酸小檗碱和水苏糖组成的组合物及其应用
CN117599036A (zh) 隐绿原酸在制备治疗和/或预防非酒精性脂肪肝产品中的用途
JP7390106B2 (ja) アテローム性動脈硬化症の治療用医薬の調製におけるトリアセチル－３－ヒドロキシフェニルアデノシンの応用
CN110946986A (zh) 一种寡肽在制备防治非酒精性脂肪肝病药物中的应用
WO2017181857A1 (zh) 一种降脂保肝组合物及其用途
AU2018446089B2 (en) Pharmaceutical use of anemoside B4 against acute gouty arthritis
CN119157865A (zh) 桤木酮及其类似物在脂肪性肝病预防及治疗中的应用
CN112370496A (zh) 枸杞叶有效成分在制备预防或治疗肝纤维化药物中的应用
KR20160100859A (ko) 아모디아퀸을 유효성분으로 함유하는 대사성 질환의 예방, 개선, 또는 치료용 조성물
CN111686239B (zh) 抗真菌化合物的应用
WO2017084631A1 (zh) 预防或治疗脂肪胰、改善脂肪胰引起的胰病变、糖尿病或其他相关病症之组合物及方法
KR20080094466A (ko) 대사증후군 치료용 약제 조성물
CN113143922A (zh) Dhc在制备动脉粥样硬化治疗制剂中的应用
RU2795163C2 (ru) Триацетил-3-гидроксифениладенозин для получения фармацевтических препаратов для уменьшения количества циркулирующих в крови моноцитов
CN103550211A (zh) 盐酸小檗碱在制备预防和/或治疗急慢性酒精性肝病药物中的应用
CN117462526A (zh) 一种大黄素琥珀酰酯类化合物在非酒精性脂肪肝病中的用途
CN117618426A (zh) 荜茇酰胺在新生儿脑损伤中的应用
CN119302965A (zh) 委陵菜酸在制备防治高血压的产品中的用途
CN120549909A (zh) 苏木酮a在制备治疗动脉粥样硬化的药物中的应用
CN120570889A (zh) Pdpk1抑制剂在代谢功能障碍相关脂肪性肝病中的应用
CN108947982A (zh) 治疗非酒精性脂肪肝病的吡嗪衍生物、组合物和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180626

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20180626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210409

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211020

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211020

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211028

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211102

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20211126

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20211130

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220824

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221129

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230117

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20230307

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20230307

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230919

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231107

R150 Certificate of patent or registration of utility model

Ref document number: 7382716

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150